Bipolar Depression
190
25
31
110
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Published Results
58 trials with published results (31%)
Research Maturity
110 completed trials (58% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
8.9%
17 terminated out of 190 trials
86.6%
+0.1% vs benchmark
33%
63 trials in Phase 3/4
53%
58 of 110 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 110 completed trials
Clinical Trials (190)
Dopamine D3 Receptor Occupancy in Bipolar Depression
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression
Theta-Burst Stimulation for Bipolar Depression
Empagliflozin Adjunctive Therapy in Bipolar Depression
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Adjunctive Bright Light Therapy in Patients With Bipolar Depression and Eveningness
Ketamine for Treatment-Resistant Bipolar Disorder
Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression
University of Iowa Interventional Psychiatry Service Patient Registry
PROgram To Enhance Cardiovascular Risk Trough an Intervention of Nutrition in Bipolar Disorder
Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression
Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder
RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)
Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression
Deep Brain Stimulation of Treatment-Resistant Bipolar Depression
Ketogenic Intervention for Bipolar Depression
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
HD-tDCS for Adolescent Bipolar Depression Targeting S1
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression